Worth Venture Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Worth Venture Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,200	Closed	-$5K	–	179
2022 Q3	$5K	Buy	+14,200	New	+$1.26M	﹤0.01%	168
2020 Q2	–	Sell	-12,100	Closed	-$15K	–	123
2020 Q1	$15K	Sell	12,100 -28,900	-70%	-$2.49M	0.01%	99
2019 Q4	$23K	Buy	41,000 +14,000	+52%	+$1.06M	0.01%	81
2019 Q3	$78K	Buy	27,000 +5,900	+28%	+$454K	0.04%	80
2019 Q2	$5K	Buy	21,100 +14,489	+219%	+$1.24M	﹤0.01%	92
2019 Q1	$55K	Buy	+6,611	New	+$613K	0.03%	82

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Worth Venture Partners's BMRN Position: Q2 2023 in Review

Worth Venture Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 3,239 shares — an estimated $315K sold.

Worth Venture Partners first reported a position in BMRN in Q4 2018 and held it in 8 quarters. The position peaked at $2.97M in Q1 2019. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Worth Venture Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Worth Venture Partners sold 3,239 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $315K.
Worth Venture Partners first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 8 quarters.
Worth Venture Partners's BioMarin Pharmaceuticals position peaked at $2.97M in Q1 2019.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.